Roger Trinh

2.9k total citations · 1 hit paper
38 papers, 1.2k citations indexed

About

Roger Trinh is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Roger Trinh has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hepatology, 26 papers in Infectious Diseases and 22 papers in Epidemiology. Recurrent topics in Roger Trinh's work include Hepatitis C virus research (31 papers), HIV/AIDS drug development and treatment (24 papers) and Liver Disease Diagnosis and Treatment (11 papers). Roger Trinh is often cited by papers focused on Hepatitis C virus research (31 papers), HIV/AIDS drug development and treatment (24 papers) and Liver Disease Diagnosis and Treatment (11 papers). Roger Trinh collaborates with scholars based in United States, Germany and France. Roger Trinh's co-authors include Thomas Podsadecki, Fred Poordad, Xavier Forns, Kosh Agarwal, Sandra Lovell, Heiner Wedemeyer, Mitchell L. Shiffman, Thomas Berg, Stefan Zeuzem and Kris V. Kowdley and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Roger Trinh

35 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

2014 646 citations Fred Poordad, Christophe Hézode et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger Trinh United States	13	1.0k	886	420	125	73	38	1.2k
Jerry O. Stern United States	16	808 0.8×	686 0.8×	546 1.3×	155 1.2×	67 0.9×	47	1.1k
Raymond T. Chung United States	9	814 0.8×	725 0.8×	367 0.9×	75 0.6×	125 1.7×	12	1.0k
S. Zaltron Italy	11	777 0.8×	728 0.8×	325 0.8×	75 0.6×	99 1.4×	23	937
Angiola Spinetti Italy	12	758 0.7×	711 0.8×	358 0.9×	82 0.7×	100 1.4×	21	949
Míriam Romero Spain	19	844 0.8×	787 0.9×	324 0.8×	47 0.4×	33 0.5×	55	1.1k
Marie Bochet France	7	1.7k 1.7×	1.6k 1.8×	591 1.4×	123 1.0×	154 2.1×	9	1.9k
Rekha Sinha United States	11	1.4k 1.4×	1.3k 1.5×	687 1.6×	280 2.2×	39 0.5×	18	1.8k
James Witek United States	17	606 0.6×	764 0.9×	495 1.2×	377 3.0×	65 0.9×	56	1.2k
Maria José Ríos-Villegas Spain	14	570 0.6×	502 0.6×	218 0.5×	78 0.6×	57 0.8×	28	692
Pilar García‐Gascó Spain	15	439 0.4×	443 0.5×	418 1.0×	267 2.1×	161 2.2×	19	833

Countries citing papers authored by Roger Trinh

Since Specialization

Citations

This map shows the geographic impact of Roger Trinh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Trinh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Trinh more than expected).

Fields of papers citing papers by Roger Trinh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Trinh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Trinh. The network helps show where Roger Trinh may publish in the future.

Co-authorship network of co-authors of Roger Trinh

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Trinh. A scholar is included among the top collaborators of Roger Trinh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Trinh. Roger Trinh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Foster, Graham R., Tarik Asselah, Lei Yang, et al.. (2019). Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS ONE. 14(1). e0208506–e0208506. 26 indexed citations

Brown, Robert S., C. Hézode, Stanley Wang, et al.. (2019). IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study. A146.1–A146. 8 indexed citations

Poordad, Fred, Shahriar Sedghi, Paul J. Pockros, et al.. (2019). Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. Journal of Viral Hepatitis. 26(8). 1027–1030. 1 indexed citations

Fontana, Robert J., Sabela Lens, Stuart McPherson, et al.. (2019). Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. Advances in Therapy. 36(12). 3458–3470. 8 indexed citations

Oberoi, Rajneet K., et al.. (2018). A Phase 1 Study to Evaluate the Effect of Crushing, Cutting Into Half, or Grinding of Glecaprevir/Pibrentasvir Tablets on Exposures in Healthy Subjects. Journal of Pharmaceutical Sciences. 107(6). 1724–1730. 21 indexed citations

Wyles, David, Michael S. Saag, Rolando M. Viani, et al.. (2017). TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. The Journal of Infectious Diseases. 215(4). 599–605. 16 indexed citations

Rockstroh, JK, Karine Lacombe, Rolando M. Viani, et al.. (2017). Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study. Journal of Hepatology. 66(1). S102–S103. 16 indexed citations

Khatri, Amit, Sandeep Dutta, Haoyu Wang, et al.. (2016). Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clinical Infectious Diseases. 62(8). 972–979. 28 indexed citations

Welzel, Tania M., Isakov Va, Roger Trinh, et al.. (2016). Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir without Ribavirin in Patients with HCV Genotype 1b with or without Compensated Cirrhosis: Pooled Analysis across 5 Clinical Trials. Journal of Hepatology. 64(2). S824–S824. 2 indexed citations

10.

Khatri, Amit, Sandeep Dutta, Martin Dunbar, et al.. (2016). Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine. Antimicrobial Agents and Chemotherapy. 60(5). 2965–2971. 27 indexed citations

11.

Khatri, Amit, et al.. (2016). Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine. Antimicrobial Agents and Chemotherapy. 60(10). 6244–6251. 17 indexed citations

12.

Feld, Jordan J., Christophe Moreno, Roger Trinh, et al.. (2015). Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. Journal of Hepatology. 64(2). 301–307. 110 indexed citations

13.

Forns, Xavier, Fred Poordad, Marcos Pedrosa, et al.. (2015). Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver International. 35(11). 2358–2362. 13 indexed citations

14.

Colombo, Massimo, Ola Weiland, Daniel E. Cohen, et al.. (2014). SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin. Hepatology. 60. 2 indexed citations

15.

Poordad, Fred, Christophe Hézode, Roger Trinh, et al.. (2014). ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. New England Journal of Medicine. 370(21). 1973–1982. 646 indexed citations breakdown →

16.

Eron, Joseph J., Jay Lalezari, Jihad Slim, et al.. (2014). Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV‐1 co‐infected patients receiving atazanavir or raltegravir ART regimens. Journal of the International AIDS Society. 17(4S3). 19500–19500. 12 indexed citations

17.

Napolitano, Laura A., Agnès Paquet, Neil Parkin, et al.. (2013). Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir. Journal of Virological Methods. 193(2). 693–696. 2 indexed citations

18.

Hermes, Ashwaq, K. Squires, Linda Fredrick, et al.. (2012). Meta-Analysis of the Safety, Tolerability, and Efficacy of Lopinavir/Ritonavir-Containing Antiretroviral Therapy in HIV-1–Infected Women. HIV Clinical Trials. 13(6). 308–323. 9 indexed citations

19.

Reynes, Jacques, Roger Trinh, Federico Pulido, et al.. (2012). Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study. AIDS Research and Human Retroviruses. 29(2). 256–265. 103 indexed citations

20.

Trinh, Roger, et al.. (2010). Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral‐experienced subjects infected with different subtypes of HIV‐1. Journal of the International AIDS Society. 13(S4).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact